Clinical Trials Directory

Trials / Completed

CompletedNCT05762380

Effect of Iron Supplements on the Growth of Enteric Pathogens

In Vitro Fecal Fermentation Following Ingestion of Iron-enriched Aspergillus Oryzae or Iron Sulfate

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Iowa State University · Academic / Other
Sex
Female
Age
18 Years – 44 Years
Healthy volunteers
Accepted

Summary

Iron supplementation is a common approach to address iron deficiency with recommendations for women of childbearing age, particularly those at risk of iron deficiency. Because of its considerably higher absorption, ferrous sulphate is the common iron compound used in iron supplements. However, concerns about iron supplements arise from the knowledge that a large portion of the supplement consumed is not absorbed. This unabsorbed iron travels to the colon and, in preclinical studies, has been shown to promote the growth of enteric pathogens at the expense of beneficial commensal bacteria and increase infection risk, including the clinical incidence of diarrhea. The objective of this study is to compare the effects of iron as ferrous sulfate (FeSO4) or FeSO4-enriched Aspergillus oryzae (Ao iron) on the growth and virulence of common enteric pathogens using an in vitro fecal fermentation model. Stool samples will be collected from women of reproductive age following ingestion of an iron supplement as either FeSO4 or Ao iron. Stool samples will be spiked with common enteric pathogens, and outcome measures will be determined following in vitro fecal fermentation.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTFerrous sulfate2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
DIETARY_SUPPLEMENTFerrous sulfate-enriched Aspergillus oryzae (Ao iron)2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)

Timeline

Start date
2022-06-14
Primary completion
2022-08-02
Completion
2022-08-02
First posted
2023-03-09
Last updated
2023-03-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05762380. Inclusion in this directory is not an endorsement.